Signal active
Organization
Contact Information
Overview
Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.
About
Biotechnology, Pharmaceutical, Therapeutics, Health Diagnostics
1995
501-1000
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Prometheus Biosciences headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Therapeutics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $91.4B in funding across 96 round(s). With a team of 501-1000 employees, Prometheus Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Prometheus Biosciences, raised $260.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
6
0
0
$951.8M
Details
3
Prometheus Biosciences has raised a total of $951.8M in funding over 3 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2020 | Private Equity | 130.0M | ||
2018 | Early Stage Venture | 10.1M | ||
2017 | Early Stage Venture | 3.7M |
Investors
Prometheus Biosciences is funded by 11 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
AGI Partners | - | FUNDING ROUND - AGI Partners | 130.0M |
Cedars Sinai | - | FUNDING ROUND - Cedars Sinai | 130.0M |
Prometheus Biosciences | - | FUNDING ROUND - Prometheus Biosciences | 130.0M |
Nestlé | - | FUNDING ROUND - Nestlé | 130.0M |
Recent Activity
There is no recent news or activity for this profile.